结直肠癌患者血清半胱氨酸蛋白酶抑制剂C的变化及临床意义  

Significance of Sera Cystatin C in Patients with Colorectal Cancer

作　　者：黄伟刚[1] 陈荣策[1] 陈福佳[2] 

机构地区：[1]广东省江门市人民医院检验科,529051 [2]广东省江门市人民医院普外科,529051

出　　处：《医学研究杂志》2008年第12期91-92,2,共3页Journal of Medical Research

摘　　要：目的探讨结直肠癌患者血清中半胱氨酸蛋白酶抑制剂C(CysC)的水平及其在肿瘤发生发展过程中的意义。方法采用免疫速率散射比浊法测定71例结直肠癌患者血清CysC的水平,并根据临床和病理特征进行分组,比较各患者组及对照组(包括40例健康体检者和48例非结直肠癌的肠道疾病患者)中CysC含量的变化。结果结直肠癌患者血清CysC的水平明显高于对照组(P<0.01),随着肿瘤的发展,患者血清CysC的含量逐渐上升;在高分化肿瘤中,CysC的含量高于低分化肿瘤,差异有统计学意义(P<0.05)。结论血清CysC含量在结直肠癌患者中明显增高,并与肿瘤的恶性程度相关,提示血清CysC水平的变化在结直肠癌的发生发展过程中起重要作用。Objective To study the clinical significance by detecting the levels of sera cystatin C（Cys C） in patients with colorectal cancer. Methods We compared the levels of sera cys C detected with the immune rate nephelometry （IRN） in 71 coloreetal cancer patients. Then we compared it in 40 healthy persons and 48 coloreetal disease patients without cancer to investigate the relationship between the level of cys C and the clinicopathological characteristics. Results The levels of cys C in colorectal cancer patients were much higher than those in the other control groups, and were significantly related to Dukes stages and the tumor differentiated degree. Conclusion The results provide convincing evidence that cys C may contribute to occurrence and development of colorectal cancer.

关 键 词：半胱氨酸蛋白酶抑制剂C 结直肠癌 临床分析 治疗方法 

分 类 号：R726.92[医药卫生—儿科] R735.3[医药卫生—临床医学]